Clinical trials: Cancer of Nasopharynx
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
- Trial name
- NCT03840421
- Testing
- gemcitabine and cisplatin, cisplatin and fluorouracil, IMRT
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), as well as to…
- Trial name
- NCT03682055
- Testing
- VK-2019
- Where
- 6 sites in United States, China and 3 more
- Volunteers
- 14 people
- Sponsor
- Cullinan Therapeutics Inc.
Head and Neck Cancer, Mucositis
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
RATIONALE: Doxepin hydrochloride may be an effective treatment for oral mucositis pain in patients undergoing radiation therapy with or without chemotherapy.
- Conditions
- Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
- Trial name
- NCT01156142
- Testing
- doxepin hydrochloride
- Where
- 120 sites in United States
- Volunteers
- 155 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
- Trial name
- NCT00003251
- Testing
- amifostine trihydrate, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Illinois Chicago
Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients…
- Trial name
- NCT07311772
- Testing
- Houyanqing Oral Liquid, Conventional Treatment for Radiation-Induced Oral Mucositis
- Where
- 16 sites in China
- Volunteers
- 386 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Head and Neck Neoplasms
Arabic PRO Measures for Head and Neck Cancer Radiotherapy.
The goal of Arabic patient-reported outcome measures during radiotherapy for head and neck cancer is to test the patient-reported outcome measure (PROM) tools.
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer
- Trial name
- PROMs (NCT06662929)
- Testing
- Radiation
- Where
- Saudi Arabia
- Volunteers
- 125 people
- Sponsor
- King Saud University
Locally Advanced Nasopharyngeal Carcinoma
ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether concurrent chemoradiotherapy is not inferior to induction chemotherapy combined with concurrent chemoradiotherapy in patients…
- Trial name
- NCT05062005
- Testing
- Induction Chemotherapy, Concurrent Chemotherapy, Definitive Radiotherapy
- Where
- China
- Volunteers
- 447 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05898256
- Testing
- Cadonilimab, Gemcitabine, Cisplatin
- Volunteers
- 20 people
- Sponsor
- Guangxi Medical University
Nasopharyngeal Cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation.
- Trial name
- NCT05628922
- Testing
- Toripalimab, Induction chemotherapy and concurrent chemoradiation
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
A total of 120 patients with pathologically confirmed locally advanced low-risk nasopharyngeal carcinoma were enrolled. They were randomly divided into two groups, with 60 patients in each group.
- Trial name
- NCT02237924
- Testing
- endostar, DDP, IMRT
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Solid Tumors
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET…
- Trial name
- NCT01324479
- Testing
- INC280
- Where
- 47 sites in United States, Australia and 13 more
- Volunteers
- 131 people
- Sponsor
- Novartis Pharmaceuticals
Nasopharyngeal Carcinoma (NPC)
A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma
Proton therapy for nasopharyngeal carcinoma can reduce radiotherapy-related toxic reactions, and some retrospective studies have found that proton therapy improves the survival of patients with nasopharyngeal carcinoma.
- Trial name
- NCT07578727
- Testing
- Proton Therapy System (ProBeam), Photon Therapy System (TrueBeam)
- Where
- 2 sites in China
- Volunteers
- 504 people
- Sponsor
- Guangzhou Concord Cancer Center
Nasopharyngeal Carcinoma
Serial Plasma EBV DNA for Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China, Hong Kong, Taiwan, Singapore and Malaysia. It is highly associated with Epstein-Barr virus (EBV).
- Trial name
- NCT02476669
- Where
- Hong Kong
- Volunteers
- 900 people
- Sponsor
- The University of Hong Kong
Head and Neck Cancer
Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent or metastatic head and neck cancer.
- Trial name
- NCT00062387
- Testing
- perifosine
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma, Head and Neck Cancer
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year.
- Conditions
- Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
- Trial name
- NCT06307314
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.
- Trial name
- NCT00563927
- Testing
- Conventional RT, Cisplatin, 5-fluorouracil
- Where
- 4 sites in China
- Volunteers
- 340 people
- Sponsor
- Hospital Authority, Hong Kong
Locally Advanced Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma
In this study, the investigators aim to compare the progression-free survival (PFS) and side effects of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients…
- Trial name
- IRCNPC (NCT03015727)
- Testing
- Docetaxel, Cisplatin, IMRT/TOMO
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
The study is to evaluate the efficacy and safety of Apatinib for later treatment of patients(after second-line treatment for locally recurrent or metastatic nasopharyngeal carcinoma), including overall survival (OS), distant…
- Trial name
- NCT03130270
- Testing
- Apatinib mesylate tablet
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Guilin Medical University, China
Hypotension, ENT Disease
Influence of the "Hypotension Probability Index" on Intraoperative and Postoperative Hypotension in ENT- and OM-Surgery
The aim of the project is to investigate whether the use of the HPI can reduce the number and duration of intra- and postoperative hypotension in ventilated patients during and two hours after extensive surgery in the head and…
- Conditions
- Hypotension, ENT Disease, Acute Kidney Injury, Anesthesia
- Trial name
- NCT04151264
- Testing
- Hypotension probability index (HPI)
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- University of Giessen
Nasopharyngeal Cancinoma (NPC)
Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients
Nasopharyngeal cancer is the sixth most common cancer and the sixth leading cause of death in Indonesia. NPC is a radiosensitive cancer so radiotherapy is the basic therapy for NPC.
- Trial name
- NCT07042711
- Testing
- Vitamin D 5,000IU Oral Tablet
- Where
- Indonesia
- Volunteers
- 300 people
- Sponsor
- Universitas Indonesia